Effect of long-term oral aspirin onserum exosome lncRNAs in patients undergoing radical resection of lung cancer

Effect of long-term oral aspirin on serumexosome lncRNAsin patients undergoing radical resection of lung cancer: a prospective cohort study

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100046947

Enrollment

Unknown

Registered

2021-05-31

Start date

2021-06-15

Completion date

Unknown

Last updated

2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Oral aspirin group:Nil

No aspirin group:Nil

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with lung cancer by imaging or histopathology; 2. Elective radical resection of lung cancer is planned; 3. Aged 40 to 70 years; 4. Informed consent.

Exclusion criteria

Exclusion criteria: 1. ASA > 3; 2. Allergy to Aspirin and other NSAIDs; 3. History of circulatory system diseases (e.g. moderate to severe iron-deficency anemia, hemophilia and thrombocytopenia); 4. Ulceration of digestive system; 5. Hemorrhagic cerebrovascular disease; 6. Hepatic renal dysfunction, cardiac insufficiency;

Design outcomes

Primary

Measure	Time frame
LncRNAs in serum exosomes;The 30-day mortality rate for patients after operation;	—

Countries

China

Contacts

Public ContactYao Linong

Tangdu Hospital of Fourth Military Medical University

yaoln@fmmu.edu.cn+86 13571837529

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026